Listen: How does Kansas City regard failure?
October 23, 2015 | Startland News Staff
In the entrepreneurial world, the word “failure” takes many definitions.
For some entrepreneurs, failure is a badge of honor, while for others it’s taboo. Regardless, failure is a part of reality amongst startups and it’s a topic that’s been examined at length in Kansas City’s entrepreneurial community.
KCUR’s Up To Date recently hosted Startland editor-in-chief Bobby Burch, Pipeline Inc. CEO Joni Cobb and CEED co-founder Adam Arredondo for a discussion on failure among startups. Below is audio from the conversation. Special thanks to KCUR for sharing its content.
How do you define failure? Does Kansas City regard failure appropriately or do we as a city have work to do? Let us know in the comments below!
Featured Business

2015 Startups to Watch
stats here
Related Posts on Startland News
Firm with deep KC ties wins Small Business of the Year thanks to tenacity, hyperlocal focus
Editor’s note: The Greater Kansas City Chamber of Commerce is a non-financial partner of Startland News, which serves as the media partner for the Small Business Superstars program. A decades-long commitment to Kansas City clients — and the belief that rising tides lift all ships — helped propel Walz Tetrick Advertising to the award stage…
How this genre-hopping KC musician is fighting back against digitized entertainment
A former college football star, Keelon Vann often found himself “running on fumes” as he chased his passion on the field — and on key. “I’d be up playing guitar until 3 a.m., which is not a joke, and somehow make it to 5:30 a.m. workouts the next day,” said Vann, a quarterback at Piper High…
New collaboration will help OP startup 3D bioprint, scale its next-gen biotech solution
A Kansas biotech startup’s new manufacturing partner will boost efforts to automate and mass produce Ronawk’s headline-grabbing Bio-Block technology — a platform that has already accelerated medical advancements in tissue therapy. “Collaboration is critical for turning research advances into commercial therapies rapidly. The complexity and diversity of modalities is so big that nobody can do…
